SummaryProstate cancer is characterized by its dependence on androgen receptor (AR) and frequent activation of PI3K signaling. We find that AR transcriptional output is decreased in human and murine tumors with PTEN deletion and that PI3K pathway inhibition activates AR signaling by relieving feedback inhibition of HER kinases. Similarly, AR inhibition activates AKT signaling by reducing levels of the AKT phosphatase PHLPP. Thus, these two oncogenic pathways cross-regulate each other by reciprocal feedback. Inhibition of one activates the other, thereby maintaining tumor cell survival. However, combined pharmacologic inhibition of PI3K and AR signaling caused near-complete prostate cancer regressions in a Pten-deficient murine prostate canc...
Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/AKT), and ma...
Prostate cancer remains a major cause of male mortality. Genetic alteration of the PI3K/AKT/mTOR pat...
Prostate cancer is an ideal target for chemoprevention. To date, chemoprevention clinical trials wit...
SummaryAlteration of the PTEN/PI3K pathway is associated with late-stage and castrate-resistant pros...
The reduction in androgen synthesis and the blockade of the androgen receptor (AR) function by chemi...
SummaryIn PTEN-mutated tumors, we show that PI3Kα activity is suppressed and PI3K signaling is drive...
Although the prognosis of patients with localized prostate cancer is good after surgery, with a favo...
Although the prognosis of patients with localized prostate cancer is good after surgery, with a favo...
Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the gold standard...
Androgen receptor (AR) signalling and the PI3K pathway mediate survival signals in prostate cancer, ...
The PI3K/AKT/mTOR pathway is frequently activated in advanced prostate cancer, due to loss of the tu...
Background: Androgen receptor (AR) and the phosphatidylinositol-3 kinase (PI3K) signaling are two of...
In 2020, an estimated 19.3 million new cancer cases were diagnosed, 7.3 % of which were cancer of ...
SummaryHyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we id...
Two recent Cancer Cell articles report the discovery of reciprocal feedback regulation between andro...
Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/AKT), and ma...
Prostate cancer remains a major cause of male mortality. Genetic alteration of the PI3K/AKT/mTOR pat...
Prostate cancer is an ideal target for chemoprevention. To date, chemoprevention clinical trials wit...
SummaryAlteration of the PTEN/PI3K pathway is associated with late-stage and castrate-resistant pros...
The reduction in androgen synthesis and the blockade of the androgen receptor (AR) function by chemi...
SummaryIn PTEN-mutated tumors, we show that PI3Kα activity is suppressed and PI3K signaling is drive...
Although the prognosis of patients with localized prostate cancer is good after surgery, with a favo...
Although the prognosis of patients with localized prostate cancer is good after surgery, with a favo...
Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the gold standard...
Androgen receptor (AR) signalling and the PI3K pathway mediate survival signals in prostate cancer, ...
The PI3K/AKT/mTOR pathway is frequently activated in advanced prostate cancer, due to loss of the tu...
Background: Androgen receptor (AR) and the phosphatidylinositol-3 kinase (PI3K) signaling are two of...
In 2020, an estimated 19.3 million new cancer cases were diagnosed, 7.3 % of which were cancer of ...
SummaryHyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we id...
Two recent Cancer Cell articles report the discovery of reciprocal feedback regulation between andro...
Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB/AKT), and ma...
Prostate cancer remains a major cause of male mortality. Genetic alteration of the PI3K/AKT/mTOR pat...
Prostate cancer is an ideal target for chemoprevention. To date, chemoprevention clinical trials wit...